28 completed, 7 withdrawn, 6 unknown, 2 not yet recruiting. 48 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 48 | Completed 28, Withdrawn 7, Unknown 6, Not yet recruiting 2, Recruiting 2, Terminated 2, Active not recruiting 1 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy Bevacizumab, Atezolizumab, Sofosbuvir - Liver Cancer | Phase 4 | Terminated | M.D. Anderson Cancer Center | 2 | 2023-03-17 | 2024-12-31 |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| Same-visit Hepatitis C Testing and Treatment (The QuickStart Study) OraQuick HCV Antibody test (OraSure Technologies, Inc), Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid), Sofosbuvir/Velpatasvir (Gilead) - Hepatitis C | Phase 4 | Unknown | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 1800 | 2022-03-09 | 2023-11-13 |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin, Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] - Chronic Hepatitis C | Phase 4 | Completed | Helwan University | 281 | 2020-11-21 | 2022-09-02 |
| Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt Sofosbuvir 400 MG/ Daclatasvir 60mg - Covid19 | Phase 4 | Completed | Alexandria University | 54 | 2020-11-01 | 2021-02-26 |
| Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg) - Hepatitis C | Phase 4 | Recruiting | Kirby Institute | 30 | 2020-02-11 | 2026-07-29 |
| The Kentucky Viral Hepatitis Treatment Study Sofosbuvir/velpatasvir (Epclusa®) - Hepatitis C, Opioid-Related Disorders | Phase 4 | Completed | Jennifer Havens | 380 | 2019-09-23 | 2026-10-20 |
| HCV Post-Exposure Prophylaxis for Health Care Workers Sofosbuvir/Velpatasvir Treatment for 14 days - Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2019-08-13 | 2020-01-21 | |
| DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Sofosbuvir 400 mg and Daclatasvir 60 mg, Sofosbuvir 400 mg and Daclatasvir 90 mg, Ribavirin - Hepatitis C, Drug Use | Phase 4 | Completed | ANRS, Emerging Infectious Diseases | 979 | 2018-11-13 | 2023-10-26 |
| Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy - Hepatitis C, HIV-1-infection | Phase 4 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 400 | 2018-10-22 | 2022-02-04 |
| Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant Zepatier, Zepatier plus Sofosbuvir - Renal Failure Chronic, Hepatitis C | Phase 4 | Withdrawn | Massachusetts General Hospital | 2018-10-01 | 2018-12-20 | |
| Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet sofosbuvir/velpatasvir tablet, sofosbuvir/velpatasvir crushed - HCV | Phase 4 | Withdrawn | Radboud University Medical Center | 2018-04-01 | 2020-12-07 | |
| Effect Of DAAs For Treatment Of HCV On Normal Kidney Sofosbuvir 400 MG Oral Tablet,, Ombitasvir/paritaprevir/ritonavir - Antiviral Drug Adverse Reaction | Phase 4 | Unknown | Assiut University | 100 | 2017-10-01 | 2017-09-29 |
| Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] - Beta-Thalassemia, Hepatitis C | Phase 4 | Completed | Tanta University | 50 | 2017-10-01 | 2019-05-23 |
| A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A elbasvir/grazoprevir, Sofosbuvir, Ribavirin - HCV | Phase 4 | Withdrawn | Fundacion SEIMC-GESIDA | 2017-07-01 | 2018-06-08 | |
| Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir Sofosbuvir 400 mg and daclatasvir 60 mg - Hepatitis C, Chronic, Chronic Renal Failure | Phase 4 | Completed | Tehran University of Medical Sciences | 95 | 2017-04-01 | 2019-09-30 |
Showing 20 of 48. Sign in to see all of them.
Hepatitis C (32) · Hepatitis C, Chronic (11) · Fibrosis (3) · Liver Diseases (3) · Acquired Immunodeficiency Syndrome (2) · Hepatitis B (2) · Kidney Failure, Chronic (2) · Recurrence (2) · Renal Insufficiency (2) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Carcinoma, Hepatocellular (1) · HIV Infections (1) · Heart Failure (1) · Liver Cirrhosis (1)
Duke University (2) · Humanity and Health Research Centre (2) · Johns Hopkins University (2) · Kirby Institute (2) · Massachusetts General Hospital (2) · Tanta University (2) · Tehran University of Medical Sciences (2) · ANRS, Emerging Infectious Diseases (1) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Alexandria University (1) · Assiut University (1) · Azienda Ospedaliera San Camillo Forlanini (1) · Brigham and Women's Hospital (1) · Catherine Anne Chappell (1) · Center For Hepatitis C, Atlanta, GA (1)
United States (24) · Egypt (5) · Australia (3) · Brazil (2) · China (2) · Iran (2) · Spain (2) · Austria (1) · Canada (1) · Germany (1) · Italy (1) · Netherlands (1) · New Zealand (1) · Pakistan (1) · Puerto Rico (1)
Raymond Chung, MD (2) · Adriano M Pellicelli, MD (1) · Andrew Muir, MD (1) · Anne Luetkemeyer, MD (1) · Asem Elfert, Prof (1) · Brian L Pearlman, MD (1) · Carmen Cobo Pelayo, MD (1) · Catherine Chappell, MD, MSc (1) · David R Nelson, MD (1) · Eslam Esmail, Ass Lecturer (1) · Gail Matthews, MbChB FRACP (1) · George KK Lau, MD (1) · George Lau, MD (1)
PMID 24067879, PMID 24209977, PMID 24720702, PMID 24997638, PMID 25557952, PMID 26890629, PMID 27237429, PMID 27782373, PMID 28785771, PMID 29316001, PMID 29507971, PMID 29535545, PMID 29906601, PMID 30946553, PMID 31504303, PMID 31994788, PMID 32156618, PMID 32356185, PMID 33208326, PMID 34226208, PMID 34255381, PMID 35026142, PMID 35182741, PMID 35657133, PMID 36694361, PMID 36722133, PMID 37088312, PMID 38960465, PMID 39656808, PMID 39702964, PMID 40019678, PMID 40607684, PMID 41017776, PMID 41027703, PMID 41255102, PMID 42852927
R01DA033777 (1), R01DA047952 (1), R34DA061732 (1), U01AI195193 (1), UM1AI068636 (1)